Misplaced Pages

Garenoxacin: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 01:52, 10 August 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation← Previous edit Latest revision as of 15:22, 9 December 2024 edit undoCitation bot (talk | contribs)Bots5,460,523 edits Added date. | Use this bot. Report bugs. | Suggested by Dominic3203 | Linked from User:Marbletan/sandbox | #UCB_webform_linked 61/2664 
(42 intermediate revisions by 29 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{drugbox
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
⚫ | verifiedrevid = 443977394
⚫ | IUPAC_name = 1-Cyclopropyl-8-(difluoromethoxy)-7--4-oxo-1,4-dihydroquinoline-3-carboxylic acid
⚫ | image = Garenoxacin.svg

<!--Clinical data-->
| tradename =
⚫ | pregnancy_category =
⚫ | legal_status =
⚫ | routes_of_administration = Oral

<!--Pharmacokinetic data-->
⚫ | bioavailability =
| protein_bound =
⚫ | metabolism =
⚫ | elimination_half-life =
⚫ | excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
⚫ | CAS_number = 194804-75-6
⚫ | ATC_prefix = J01
⚫ | ATC_suffix = MA19
⚫ | PubChem = 124093
⚫ | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
⚫ | DrugBank =
| UNII_Ref = {{fdacite|correct|FDA}} | UNII_Ref = {{fdacite|correct|FDA}}
| UNII = V72H9867WB | UNII = V72H9867WB
⚫ | verifiedrevid = 443450244
⚫ | IUPAC_name = 1-cyclopropyl-8-(difluoromethoxy)-7--4-oxo-1,4-dihydroquinoline-3-carboxylic acid
⚫ | image = Garenoxacin.svg
⚫ | CAS_number = 91421-42-0
⚫ | ATC_prefix = J01
⚫ | ATC_suffix = MA19
⚫ | PubChem = 124093
⚫ | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
⚫ | DrugBank =
| KEGG_Ref = {{keggcite|correct|kegg}} | KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04031 | KEGG = D04031
| ChEBI_Ref = {{ebicite|changed|EBI}}
⚫ | C = 23 |H = 20 |F = 2 |N = 2 |O = 4
| ChEBI = 131716
| molecular_weight = 426.412 ]/]
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
⚫ | bioavailability =
| protein_bound = | ChemSpiderID = 110579
| smiles = FC(F)Oc1c(ccc2c1N(/C=C(\C2=O)C(=O)O)C3CC3)c4ccc5c(c4)CN5C
⚫ | metabolism =
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
⚫ | elimination_half-life =
| StdInChI = 1S/C23H20F2N2O4/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30)/t11-/m1/s1
⚫ | excretion =
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
⚫ | pregnancy_category =
| StdInChIKey = NJDRXTDGYFKORP-LLVKDONJSA-N
⚫ | legal_status =

⚫ | routes_of_administration = Oral
<!--Chemical data-->
⚫ | C=23 | H=20 | F=2 | N=2 | O=4
}} }}


'''Garenoxacin''' (]) is a quinolone antibiotic for the treatment of gram-positive and gram-negative bacterial infections. '''Garenoxacin''' (]) is a ] ] for the treatment of ] and ] bacterial infections.<ref name="pmid18790608">{{cite journal | vauthors = Takagi H, Tanaka K, Tsuda H, Kobayashi H | title = Clinical studies of garenoxacin | journal = International Journal of Antimicrobial Agents | volume = 32 | issue = 6 | pages = 468–74 | date = December 2008 | pmid = 18790608 | doi = 10.1016/j.ijantimicag.2008.06.032 | doi-access = free }}</ref>


It was discovered by Toyama Chemical Co., Ltd. of Tokyo, Japan, and is currently being marketed in ] under the tradename Geninax. ] holds worldwide rights for garenoxacin, except for Japan, ], and ]. Garenoxacin was discovered by Toyama Chemical Co., Ltd. of Tokyo, Japan, and is currently being marketed in ] under the tradename Geninax. ] holds worldwide rights for garenoxacin, except for Japan, ], and ].{{cn|date=January 2023}}


On February 13, 2006, Schering-Plough announced that the ] ] has accepted the New Drug Application (NDA) for garenoxacin, and has been granted a 10-month review.<ref>{{cite web |url=http://www.drugs.com/nda/garenoxacin_060213.html |title=Drugs.com, Schering-Plough Reports Garenoxacin NDA Accepted for FDA Review |accessdate=2008-03-25 |format= |work= }}</ref> On February 13, 2006, ] announced that the ] ] had accepted the New Drug Application (NDA) for garenoxacin, and had been granted a 10-month review.<ref>{{cite web |url=https://www.drugs.com/nda/garenoxacin_060213.html |title=Drugs.com, Schering-Plough Reports Garenoxacin NDA Accepted for FDA Review |access-date=2008-03-25 }}</ref> As of 2015, however, it has not been approved in the US.{{cn|date=January 2023}}


Schering-Plough later withdrew its application to the United States Food and Drug Administration, FDA, (August 20, 2006) for approval of the antibiotic Garenoxacin.<ref>http://www.fiercebiotech.com/story/schering-plough-pulls-its-garenoxacin-app/2006-08-21</ref> Schering-Plough later withdrew its application to the United States Food and Drug Administration, FDA, (August 20, 2006) for approval of the antibiotic Garenoxacin.<ref>{{Cite web | url=http://www.fiercebiotech.com/story/schering-plough-pulls-its-garenoxacin-app/2006-08-21 | title=Schering-Plough pulls its garenoxacin app| date=20 August 2006}}</ref>


The ] (EMA) had also been formally notified by Schering-Plough Europe (July 25, 2007) of its decision to withdraw the application for a centralized marketing authorization for garenoxacin as well.<ref>{{Cite web |url=http://www.medicalnewstoday.com/articles/78052.php |title=Schering-Plough Europe Withdraws Its Marketing Authorisation Application For Garenoxacin Mesylate |access-date=2009-05-30 |archive-date=2007-08-08 |archive-url=https://web.archive.org/web/20070808183432/http://www.medicalnewstoday.com/articles/78052.php |url-status=dead | publisher = MediLexicon International Ltd | date = 28 July 2007 }}</ref><ref>{{cite web | title=Garenoxacin mesylate: Withdrawn application | website=] (EMA) | date=17 September 2018 | url= https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/garenoxacin-mesylate | access-date=13 July 2020}}</ref><ref>{{cite press release | title=Schering-Plough Europe withdraws its marketing authorisation applicationfor Garenoxacin mesylate | website=] (EMA) | url=https://www.ema.europa.eu/en/news/schering-plough-europe-withdraws-its-marketing-authorisation-applicationfor-garenoxacin-mesylate | access-date=13 July 2020}}</ref> Based on the CHMP review of the data regarding safety and efficacy (risk/benefit), the CHMP considered the application for garenoxacin to be unapprovable.<ref>{{cite web | title = Withdrawal Assessment report for Garenoxacin Mesylate (garenoxacin) | url = https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-garenoxacin-mesylate_en.pdf | publisher = European Medicines Agency | date = 18 October 2007 }}</ref>
The European Medicines Agency (EMEA) had also been formally notified by Schering-Plough Europe (July 28 2007) of its decision to withdraw the application for a centralized marketing authorization for Garenoxacin as well.
<ref>http://www.medicalnewstoday.com/articles/78052.php</ref><ref>http://www.emea.europa.eu/humandocs/PDFs/EPAR/garenoxacinmesylate/34117407en.pdf</ref><ref>http://www.emea.europa.eu/humandocs/PDFs/EPAR/garenoxacinmesylate/H-747-WAR.pdf</ref>

Based on the CHMP review of the data regarding safety and efficacy, (risk/benefit) the CHMP considered the application for Garenoxacin to be unapprovable. <ref> http://www.emea.europa.eu/humandocs/PDFs/EPAR/garenoxacinmesylate/H-747-WAR.pdf</ref>

==See also==
*]
*]


==References== ==References==
Line 47: Line 61:
{{QuinoloneAntiBiotics}} {{QuinoloneAntiBiotics}}


] ]
] ]
] ]
] ]
]




{{antibiotic-stub}} {{antibiotic-stub}}

]
]

Latest revision as of 15:22, 9 December 2024

Chemical compound Pharmaceutical compound
Garenoxacin
Clinical data
Routes of
administration		Oral
ATC code
Identifiers
IUPAC name
  • 1-Cyclopropyl-8-(difluoromethoxy)-7--4-oxo-1,4-dihydroquinoline-3-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H20F2N2O4
Molar mass426.420 g·mol
3D model (JSmol)
SMILES
  • FC(F)Oc1c(ccc2c1N(/C=C(\C2=O)C(=O)O)C3CC3)c4ccc5c(c4)CN5C
InChI
  • InChI=1S/C23H20F2N2O4/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30)/t11-/m1/s1
  • Key:NJDRXTDGYFKORP-LLVKDONJSA-N
  (what is this?)  (verify)

Garenoxacin (INN) is a quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections.

Garenoxacin was discovered by Toyama Chemical Co., Ltd. of Tokyo, Japan, and is currently being marketed in Japan under the tradename Geninax. Schering-Plough holds worldwide rights for garenoxacin, except for Japan, South Korea, and China.

On February 13, 2006, Schering-Plough announced that the United States Food and Drug Administration had accepted the New Drug Application (NDA) for garenoxacin, and had been granted a 10-month review. As of 2015, however, it has not been approved in the US.

Schering-Plough later withdrew its application to the United States Food and Drug Administration, FDA, (August 20, 2006) for approval of the antibiotic Garenoxacin.

The European Medicines Agency (EMA) had also been formally notified by Schering-Plough Europe (July 25, 2007) of its decision to withdraw the application for a centralized marketing authorization for garenoxacin as well. Based on the CHMP review of the data regarding safety and efficacy (risk/benefit), the CHMP considered the application for garenoxacin to be unapprovable.

References

  1. Takagi H, Tanaka K, Tsuda H, Kobayashi H (December 2008). "Clinical studies of garenoxacin". International Journal of Antimicrobial Agents. 32 (6): 468–74. doi:10.1016/j.ijantimicag.2008.06.032. PMID 18790608.
  2. "Drugs.com, Schering-Plough Reports Garenoxacin NDA Accepted for FDA Review". Retrieved 2008-03-25.
  3. "Schering-Plough pulls its garenoxacin app". 20 August 2006.
  4. "Schering-Plough Europe Withdraws Its Marketing Authorisation Application For Garenoxacin Mesylate". MediLexicon International Ltd. 28 July 2007. Archived from the original on 2007-08-08. Retrieved 2009-05-30.
  5. "Garenoxacin mesylate: Withdrawn application". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 July 2020.
  6. "Schering-Plough Europe withdraws its marketing authorisation applicationfor Garenoxacin mesylate". European Medicines Agency (EMA) (Press release). Retrieved 13 July 2020.
  7. "Withdrawal Assessment report for Garenoxacin Mesylate (garenoxacin)" (PDF). European Medicines Agency. 18 October 2007.
Antibacterials that inhibit nucleic acid (J01E, J01M)
Antifolates
(inhibit bacterial
purine metabolism,
thereby inhibiting
DNA and RNA
synthesis)
DHFR inhibitor
Sulfonamides
(DHPS inhibitor)
Short-acting
Intermediate-acting
Long-acting
Other/ungrouped
Combinations
Other DHPS inhibitors
Quinolones
(inhibit bacterial
topoisomerase
and/or DNA gyrase,
thereby inhibiting
DNA replication)
1st generation
Fluoroquinolones
2nd generation
3rd generation
4th generation
Veterinary
Newer non-fluorinated
Related (DG)
Anaerobic DNA
inhibitors
Nitroimidazole derivatives
RNA synthesis
Rifamycins/
RNA polymerase
Lipiarmycins


Stub icon

This systemic antibiotic-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Garenoxacin: Difference between revisions Add topic